Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MNOV vs OBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MNOV Captures Overall Composite Edge (50.2 HOLD vs 41.1 SELL), While OBIO Leads 3–2 on Growth & Valuation Pillars

MNOV Overall Winner 6-Pillar Tally: MNOV 2 – 3 OBIO (1 Tie) Matrix Metrics: MNOV 7 – 3 OBIO

As of Nov 20, 2026, Medicinova, Inc. (MNOV) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (50.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. MNOV trades at $1.31 (8.5x Forward P/E, -1232.2% operating margin) versus OBIO at $6.58 (N/M Forward P/E, -195.4% operating margin).

  • Growth vs. Quality Trade-Off: MNOV earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. OBIO 41.1/100 SELL) and 0.59β · 38% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MNOV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4); meanwhile OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MNOV vs OBIO
MNOV NASDAQ Head-to-Head Winner
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
TTM Revenue $935,717
Forward P/E 8.5x
Beta / 30D Vol 0.59β · 38% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 36
RSI-14: 36.4 · SMA20: $1.40 · SMA50: $1.74
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.58
-6.0% 1D
Market Cap $550.9M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.18β · 88% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 55
RSI-14: 54.9 · SMA20: $6.19 · SMA50: $6.01

6-Pillar Scorecard Institutional Category Breakdown (MNOV 2 – 3 OBIO)

Columns: Metric · MNOV · OBIO
1. Valuation Multiples MNOV
Forward P/E 8.5x N/M
Trailing P/E 8.5x N/M
PEG Ratio N/M N/M
EV / Revenue 42.5x 17.9x
2. Growth & Scale OBIO
Revenue Growth (YoY) +12.4% -89.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $935,717 $31M
Market Cap $65.1M $550.9M
3. Profitability & Quality OBIO
Gross Margin 42.2% 99.6%
Operating Margin -1232.2% -195.4%
Net Profit Margin 0.0% -182.5%
Return on Equity (ROE) -24.8% -182.3%
4. Balance Sheet & Cash Flow MNOV
Cash Generation (TTM) -$9.1M -$64M
Cash Flow Margin N/A N/A
Net Cash / Leverage $25M Net Cash $9.0M Net Debt (4.72x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 140.1% (50th %ile) 78.2% (21st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MNOV (7) vs OBIO (3)
Institutional Metric MNOV OBIO Criterion Row Edge
Market Capitalization
Scale
$65.1M $550.9M Larger Scale OBIO
Trailing P/E Ratio
Valuation
8.5x N/M Lower Multiple MNOV
Forward P/E Ratio
Valuation
8.5x N/M Lower Multiple MNOV
Revenue Growth (YoY)
Growth
+12.4% -89.4% Higher Growth MNOV
Operating Margin (TTM)
Profitability
-1232.2% -195.4% Higher Margin OBIO
Net Profit Margin
Profitability
0.0% -182.5% Higher Margin MNOV
Return on Equity (ROE)
Capital Efficiency
-24.8% -182.3% Higher ROE MNOV
52-Week Range Position
Momentum
3% ($1–$4) 72% ($3–$8) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
0.59β · 38% Vol 1.18β · 88% Vol Lower Realized Risk MNOV
Unified Institutional Score
Composite Signal
50.2 / 100 (HOLD) 41.1 / 100 (SELL) Higher Composite MNOV
Trailing 12M Revenue (USD)
Operating Scale
$935,717 $31M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
42.2% 99.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 42.5x EV/Rev N/M PEG · 17.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.1M ($25M Net Cash) -$64M ($9.0M Net Debt (4.72x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +27.38 pp
MNOV: -7.09% · OBIO: +20.29%
3M Horizon OBIO +35.34 pp
MNOV: -14.38% · OBIO: +20.96%
6M Horizon OBIO +68.5 pp
MNOV: -6.43% · OBIO: +62.07%
1Y Horizon OBIO +49.59 pp
MNOV: -8.39% · OBIO: +41.2%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MNOV Revenue OBIO Revenue MNOV Op. Margin OBIO Op. Margin Margin Leader
FY2012 $0M N/A -1363.8% N/A MNOV
FY2021 $0M N/A -253.0% N/A MNOV
FY2022 N/A $0M N/A -924.3% OBIO
FY2023 $0M $0M -990.0% -1866.2% MNOV
FY2024 N/A $0M N/A -2437.5% OBIO
FY2025 $0M $30M -3242.5% -154.7% OBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 140.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OBIO CONSOLIDATION
36d in phase · OBV ACCUMULATION
Current IV 78.2%
IV Percentile 21st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MNOV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.1M market capitalization and -1232.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $550.9M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MNOV vs OBIO Key Questions & Quantitative Answers

As of Nov 20, 2026, Medicinova, Inc. (MNOV) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (50.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. MNOV trades at $1.31 (8.5x Forward P/E, -1232.2% operating margin) versus OBIO at $6.58 (N/M Forward P/E, -195.4% operating margin). Growth vs. Quality Trade-Off: MNOV earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. OBIO 41.1/100 SELL) and 0.59β · 38% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MNOV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4); meanwhile OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: MNOV posts +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin), compared with OBIO at -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin). Across the 6-period historical trajectory (FY2012 to FY2025), MNOV cumulative revenue shifted N/A while OBIO shifted N/A. In operating R&D and SG&A reinvestment, MNOV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OBIO.

MNOV screens cheaper on headline valuation multiples. MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin), whereas OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNOV (-24.8% ROE) versus OBIO (-182.3% ROE) capital efficiency.

In options market volatility and institutional positioning, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk). By comparison, OBIO carries 78.2% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.18β · 88% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.